|
Colitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that SBP1 was mainly located on epithelial cells and was significantly increased in patients with active CD.SBP1 was the target gene of miR-122. miR-122 expression was downregulated while SBP1 expression was upregulated under TNBS-induced colitis or oxidative stress.
|
31019652 |
2019 |
|
Crohn Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that SBP1 was mainly located on epithelial cells and was significantly increased in patients with active CD.SBP1 was the target gene of miR-122. miR-122 expression was downregulated while SBP1 expression was upregulated under TNBS-induced colitis or oxidative stress.
|
31019652 |
2019 |
|
Dwarfism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Identification of a Novel SBP1-Containing SCF<sup>SFB</sup> Complex in Wild Dwarf Almond (<i>Prunus tenella</i>).
|
31708966 |
2019 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results showed that SBP1 expression was significantly downregulated in ICC tumor tissues, especially in tumor tissues from ICC patients with recurrence or tumor vascular invasion, compared with that in peritumoral tissues (all <i>P</i> < 0.05).
|
30662608 |
2018 |
|
Coronary Artery Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Previous studies have shown that long-term administration of SBP (1-2 pills three times daily, for at least 6 months) for treatment of CAD is effective and safe, with a significant, long-term effect.
|
29444778 |
2018 |
|
Benign Ovarian Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
The percent of anti-SBP1-positive sera was higher in POF (P = 0.02), irregular ovulation (P = 0.001), unexplained causes (P = 0.02), late (III-IV)-stage OvCa (P = 0.02) but was not significant in endometriosis, benign ovarian tumors/cysts, early stage (I-II) OvCa or uterine cancer compared to healthy controls.
|
27965399 |
2017 |
|
Endometriosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The percent of anti-SBP1-positive sera was higher in POF (P = 0.02), irregular ovulation (P = 0.001), unexplained causes (P = 0.02), late (III-IV)-stage OvCa (P = 0.02) but was not significant in endometriosis, benign ovarian tumors/cysts, early stage (I-II) OvCa or uterine cancer compared to healthy controls.
|
27965399 |
2017 |
|
Kidney Failure, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to assess the sensitivity of urinary SBP1 levels as an early detection of AKI using animal models such as cisplatin or ischemia/reperfusion (I/R).
|
28665768 |
2017 |
|
Premature Menopause
|
0.010 |
Biomarker
|
disease |
BEFREE |
The percent of anti-SBP1-positive sera was higher in POF (P = 0.02), irregular ovulation (P = 0.001), unexplained causes (P = 0.02), late (III-IV)-stage OvCa (P = 0.02) but was not significant in endometriosis, benign ovarian tumors/cysts, early stage (I-II) OvCa or uterine cancer compared to healthy controls.
|
27965399 |
2017 |
|
Ovarian Failure, Premature
|
0.010 |
Biomarker
|
disease |
BEFREE |
The percent of anti-SBP1-positive sera was higher in POF (P = 0.02), irregular ovulation (P = 0.001), unexplained causes (P = 0.02), late (III-IV)-stage OvCa (P = 0.02) but was not significant in endometriosis, benign ovarian tumors/cysts, early stage (I-II) OvCa or uterine cancer compared to healthy controls.
|
27965399 |
2017 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
The ability of anti-SBP1 alone to discriminate infertility or OvCa from controls or when combined with anti-TP53 and CA125, to identify OvCa was evaluated by comparing the area under the curve (AUC) in ROC analysis.
|
27965399 |
2017 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
The ability of anti-SBP1 alone to discriminate infertility or OvCa from controls or when combined with anti-TP53 and CA125, to identify OvCa was evaluated by comparing the area under the curve (AUC) in ROC analysis.
|
27965399 |
2017 |
|
Chronic Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We also observed high accumulation of ARP-modified SBP1 in the RBCs of patients with chronic kidney disease.
|
28867194 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
The ability of anti-SBP1 alone to discriminate infertility or OvCa from controls or when combined with anti-TP53 and CA125, to identify OvCa was evaluated by comparing the area under the curve (AUC) in ROC analysis.
|
27965399 |
2017 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that SBP1 can serve as a potential target to suppress gastric cancer.
|
23483240 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
N-myc downstream regulated gene 1 (NDRG1/Cap43/Drg-1) has previously been shown to be dysregulated in esophageal squamous cell carcinoma (ESCC).
|
23192272 |
2013 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that SBP1 can serve as a potential target to suppress gastric cancer.
|
23483240 |
2013 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
|
22481237 |
2012 |
|
Prostatic Intraepithelial Neoplasias
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CD44s is decreased in both PIN and cancer; Drg-1, E-cadherin, KAI-1, RKIP, and SSeCKS show similar expression between benign epithelia and PIN, but are downregulated in invasive cancer; whereas, maspin, MKK4, Nm23 and PTEN are upregulated in PIN and downregulated in cancer.
|
22886631 |
2012 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
|
22481237 |
2012 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
|
22481237 |
2012 |
|
Tumor Angiogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
|
22481237 |
2012 |
|
Selenium deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Because selenium-binding protein 1 (SELENBP1, SBP1, hSP56) has been shown to bind selenium covalently and selenium deficiency has been associated with esophageal adenocarcinoma (EAC), we examined its role in EAC development and its potential effect on chemosensitivity in the presence of selenium.
|
20332323 |
2010 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Because selenium-binding protein 1 (SELENBP1, SBP1, hSP56) has been shown to bind selenium covalently and selenium deficiency has been associated with esophageal adenocarcinoma (EAC), we examined its role in EAC development and its potential effect on chemosensitivity in the presence of selenium.
|
20332323 |
2010 |
|
Familial multiple trichoepitheliomata
|
0.010 |
Biomarker
|
disease |
BEFREE |
Because selenium-binding protein 1 (SELENBP1, SBP1, hSP56) has been shown to bind selenium covalently and selenium deficiency has been associated with esophageal adenocarcinoma (EAC), we examined its role in EAC development and its potential effect on chemosensitivity in the presence of selenium.
|
20332323 |
2010 |